最新更新 :
19/11/2024
Infostab
药品清单
简要表
搜索兼容性
Y 站点兼容性表
引用文献
研究小組
valistab
海报
鏈接
贊助商
作者
使用指南
时讯
Carboplatin
化学式
商品名
商品名仅供参考, 药品所用的辅料可能依国家或厂商不同有所不同。
Acoplasic
墨西哥
Axicarb
德国
Balidon
哥伦比亚
Blastocarb
哥伦比亚, 墨西哥, 智利, 秘鲁
Boplatex
厄瓜多尔, 哥伦比亚, 墨西哥
Carbip
墨西哥
Carbodex
土耳其
Carboeen
印度
Carbokebir
阿根廷
Carbokem
印度
Carbol
秘鲁
Carbomedac
瑞典
Carboplat
墨西哥, 德国, 阿根廷
Carboplatin
丹麦, 伊朗, 冰岛, 加拿大, 卢森堡, 印度, 埃及, 奥地利, 巴西, 希腊, 摩洛哥, 新西蘭, 比利时, 沙特阿拉伯, 澳大利亚, 爱尔兰, 美国, 芬兰
Carboplatine
摩洛哥, 法国, 瑞士
Carboplatino
哥伦比亚, 智利, 西班牙, 阿根廷
Carbosin
埃及, 希腊, 比利时, 马来西亚
Cycloplatin
匈牙利, 波兰
Emorzym
希腊
Megaplatin
希腊
Nuvaplast
墨西哥
Paraplatin
丹麦, 匈牙利, 卢森堡, 墨西哥, 奥地利, 希腊, 意大利, 挪威, 比利时, 波兰, 瑞典, 瑞士, 美国, 芬兰, 英国, 荷兰, 西班牙, 阿联酋
Paraplatine
摩洛哥, 法国, 突尼斯
Platinwas
西班牙
引用文献 : Carboplatin
种类
出版物
3
文献
Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
57
文献
Mayron D, Gennaro AR.
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.
Am J Health-Syst Pharm 1996 ; 53: 294-304.
81
文献
Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84
文献
Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
85
文献
Trissel LA, Bready BB.
Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 1716-1719.
99
文献
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
163
文献
Sewell GJ, Allsopp M, Collinson MP, Tyrrell C, Prentice AJ, Copplestone JA.
Stability studies on admixtures of 5-fluorouracil with carboplatin and 5-fluorouracil with heparin for administration in continuous infusion regimens.
J Clin Pharm Ther 1994 ; 19: 127-133.
164
文献
Benaji B, Dine T, Luyckx M, Brunet C, Goudaliez F, Mallevais ML, Cazin M, Gressier B, Cazin JC.
Stability and compatibility of cisplatin and carboplatin with PVC infusion bags.
J Clin Pharm Ther 1994 ; 19: 95-100.
166
文献
Rochard E, Barthes D, Courtois P.
Stability and compatibility study of carboplatin with three portable infusion pump reservoirs.
Int J Pharm 1994 ; 101: 257-262.
169
文献
Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
244
文献
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249
文献
Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251
文献
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
300
文献
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301
文献
Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307
文献
Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
334
文献
Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335
文献
Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
409
文献
Cheung YW, Cradock JC, Vishnuvajjala BR, Flora KP.
Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions.
Am J Hosp Pharm 1987 ; 44: 124-130.
484
文献
Northcott M, Allsopp MA, Powell H, Sewell GJ.
The stability of carboplatin, diamorphine, 5-fluorouracil and mitozantrone infusions in an ambulatory pump under storage and prolonged “in use” conditions.
J Clin Pharm Ther 1991 ; 16: 123-129.
486
文献
Diaz Amador F, Sevilla Azzati E, Herreros de Tajeda y Lopez-Coterilla A.
Stability of carboplatin in polyvinyl chloride bags.
Am J Health-Syst Pharm 1998 ; 55: 602, 604.
492
文献
Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
645
文献
Sewell GJ, Riley CM, Rowland CG.
The stability of carboplatin in ambulatory continuous infusion regimes.
J Clin Pharm Ther 1987 ; 12: 427-432.
872
文献
Zhang YP, Xu QA, Trissel LA, Gilbert DL, Martinez F.
Compatibility and stability of paclitaxel combined with cisplatin and with carboplatin in infusion solutions.
Ann Pharmacotherapy 1997 ; 31: 1465-1470.
905
文献
Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921
文献
Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1026
文献
Mayron D, Gennaro AR.
Stability and compatibility of topotecan hydrochloride with selected drugs.
Am J Health-Syst Pharm 1999 ; 56: 875-881.
1410
文献
Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415
文献
Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423
文献
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1496
文献
Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428.
1520
实验室
Etude de stabilité des médicaments en Ecoflac®
B Braun 2001
1625
文献
Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1662
文献
Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1667
文献
Valière C, Arnaud P, Caroff E, Dauphin JF, Clément G, Brion F.
Stability and compatibility study of a carboplatin solution in syringes for continuous ambulatory infusion.
Int J Pharm 1996 ; 138: 125-128.
1734
文献
Hadfield JA, McGown AT, Dawson MJ, Thatcher N, Fox BW.
The suitability of carboplatin solutions for 14-day continuous infusion by ambulatory pump : an HPLC-dynamic FAB study.
J Pharm Biomed Anal 1993 ; 11: 723-727.
1925
文献
Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1950
文献
Trissel LA, Yanping Z.
Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration.
J Oncol Pharm Practice 2004 ; 10: 191-195.
1953
文献
Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982
文献
Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2108
文献
Trusley C, Kupiec TC, Trissel LA.
Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.
Int J Pharm Compound 2006 ; 10: 230-232.
2203
文献
Kaestner S, Sewell G.
A sequential temperature cycling study for the investigation of carboplatin infusion stability to facilitate 'dose-banding'.
J Oncol Pharm Practice 2007 ; 13: 119-126.
2242
文献
Lederer M, Leipzig-Pagani E.
A note on the solution chemistry of carboplatin in aqueous solutions.
Int J Pharm 1998 ; 167, 1-2: 223-228.
2243
文献
Pujol M, Girona V, Prat J, Munoz M, De Bolos J.
Degradation pathway of carboplatin in aqueous solution.
Int J Pharm 1997 ; 146: 263-269.
2244
文献
Prat J, Pujol M, Girona V, Munoz M, Sol? L-A.
Stability of carboplatin in 5% glucose solution in glass, polyethylene and polypropylene containers.
J Pharm Biomed Anal 1994 ; 12, 1: 81-84.
2245
文献
Torres F, Girona V, Puiol M, Prat J, de Bolos J.
Stability of carboplatin in 5% glucose solution exposed to light.
Int J Pharm 1996 ; 129: 275-277.
2247
文献
Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
2253
文献
Curis E, Provost K, Bouvet D, Nicolis I, Crauste-manciet S, Brossard D, B?nazeth S.
Carboplatin and oxaliplatin decomposition in chloride medium, monitored by XAS.
J Synchrotron Rad 2001 ; 8: 716-718.
2254
文献
Curis E, Provost K, Nicolis I, Bouvet D, B?nazeth S, Crauste-Manciet S, Brion F, Brossard D.
Carboplatin decomposition in aqueous solution with chloride ions monitored by X-ray absorption spectroscopy.
New J Chem 2000 ; 24: 1003-1008.
2262
文献
Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3277
文献
Yang Z, Cameron S, Paul H.
Stability of Carboplatin, Paclitaxel, and Docetaxel with Acetyl-L-carnitine During Simulated Y-site Administration.
Int J Pharm Compound 2012 ; 16, 1 : 82-85.
3286
文献
Okamoto Y, Tazumi K, Sanada Y, Tsugane M, Uejima E.
Light-induced Deterioration Test of Carboplatin under Clinical Settings.
Yakugaku Zasshi 2010 ; 130, 10: 1369-1374.
3341
文献
Trittler R, Jung B, Strehl E.
Ist teurer immer auch besser? Analytiklabor der Apotheke unterstütz Einkauf sentcheidungen bei Carboplatin-Präparaten.
Krankenhauspharmazie 2001 ; 7: 331-333.
3474
实验室
Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009
3574
实验室
Ondansetron - Résumé des caractéristiques du produit
Accord Healthcare France SAS 2013
3602
实验室
Mesna (Uromitexan®)- Summary of Product Characteristics
Baxter SAS 2013
3670
文献
Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30.
3743
文献
Allsopp M.A, Sewell G.J, Rowland C.G, Riley C.M, Schowen R.L.
The degradation of carboplatin in aqueous solutions containing chloride or other selected nucleophiles.
Int J Pharm 1991 ; 69: 197-210.
3830
文献
Myers A.Ls, Zhang Y-P, Kawedia L, Trinh V.A, Tran H, Smith J.A, Kramer M.A.
Stability study of carboplatin infusion solutions in 0.9% sodium chloride in polyvinyl chloride bags.
J Oncol Pharm Practice 2016 ; 22: 31-36.
4120
文献
Vazquez-Sanchez R, Sanchez-Rubio-Ferrandez J, Cordoba-Diaz D, Cordoba-Diaz M, Molina-Garcia T.
Stability of carboplatin infusion solutions used in desensitization protocol.
J Oncol Pharm Practice 2018 25,5:1076?1081
4205
文献
Choi S, O La H, Kim K, Kim S, Hwangbo S.
Stability of Carboplatin in normal saline : dependence on initial dilution concentration and storage time.
J Kor Soc Hosp Pharm 2006 ;23,3:219-224
4310
文献
Mizuta N, Nakagawa T, Yamamoto K, Nishioka T, Kume M, Makimoto H, Yano I, Minami H, Hiral M.
Compatibility and Stability of Nab-Paclitaxel in Combination with Other Drugs.
Kaohsiung J Med Sci 2017 ; 63, 1: E9-E16.
Mentions Légales